Benzyl isothiocyanate inhibits inflammasome activation in E. coli LPS-stimulated BV2 cells

CHANG-MIN LEE1*, DAE-SUNG LEE2*, WON-KYO JUNG3*, JONG SU YOO2, MI-JIN YIM2, YUNG HYUN CHOI4, SAEGWANG PARK5, SU-KIL SEO5, JUNG SIK CHOI6, YOUNG-MIN LEE6, WON SUN PARK7 and IL-WHAN CHOI5

1Department of Molecular Microbiology and Immunology, Warren Alpert School of Medicine, Providence, RI 02912, USA; 2National Marine Biodiversity Institute of Korea, Seocheon; 3Department of Biomedical Engineering, and Center for Marine-Integrated Biomedical Technology (BK21 Plus), Pukyong National University; 4Department of Biochemistry, College of Oriental Medicine, Dongeui University; 5Department of Microbiology and Immunology, College of Medicine, Inje University; 6Department of Internal Medicine, Busan Paik Hospital, College of Medicine, Inje University, Busan; 7Department of Physiology, Kangwon National University School of Medicine, Chuncheon, Republic of Korea

Received February 10, 2016; Accepted June 28, 2016

DOI: 10.3892/ijmm.2016.2667

Abstract. Inflammasomes are multi-protein complexes that play a crucial role in innate immune responses. Benzyl isothiocyanate (BITC) is a naturally occurring compound found in cruciferous vegetables, and BITC exhibits potential as a chemopreventive agent. However, whether BITC exerts inflammasome-mediated regulatory effects on neuroinflammation is unknown. In this study, we examined the effects of BITC on inflammasome-mediated regulatory effects on IL-1β production in E. coli lipopolysaccharide (LPS)-stimulated BV2 microglial cells. IL-1β production is tightly regulated at the post-translational level through the inflammasome. We measured the levels of IL-1β produced from the LPS-exposed BV2 microglial cells using enzyme-linked immunosorbent assays (ELISAs). The BITC regulatory mechanisms in inflammasome-mediated cellular signaling pathways were examined by RT-PCR, western blot analysis and electrophoretic mobility shift assays. BITC inhibited the secretion of IL-1β induced by LPS in the BV2 microglial cells. BITC inhibited inflammasome activation and NLR family, pyrin domain containing 3 (NLRP3)-mediated caspase-1 activation, and decreased the levels of inflammasome activation pro-inflammatory mediators, including mitochondrial reactive oxygen species (ROS) and adenosine triphosphate (ATP) secretion in the LPS-stimulated BV2 microglial cells. Furthermore, we demonstrated that nuclear factor-kB (NF-kB) activation induced by LPS was inhibited by BITC, which may contribute to the attenuated secretion of IL-1β. These BITC-mediated inhibitory effects on IL-1β expression may thus regulate neuroinflammation through the inflammasome-mediated signaling pathway.

Introduction

Interleukin-1β (IL-1β) is a pivotal pro-inflammatory cytokine that has been linked to the pathogenesis of a broad spectrum of acute and chronic inflammatory diseases (1). IL-1β is synthesized as a precursor in the cytosol in response to various stimuli. A low level of IL-1β in vivo can evoke various mediators, which induce an inflammatory response (2). IL-1β is considered an important pro-inflammatory cytokine in the brain and plays a critical role in the progression of neuroinflammation (3). Neuroinflammation is a well-known factor in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS) (4). IL-1β is produced by lipopolysaccharide (LPS)-stimulated BV2 microglia. LPS induces neuroinflammation by activating inflammatory cells, including astrocytes and microglial cells (5). In a previous study, it was shown that the systemic injection of LPS led to neuroinflammatory responses in the brain, which then led to amyloid-β accumulation (6).

As regards IL-1β biological activity, mature IL-1β is regulated through cytosolic multi-protein complexes referred to as inflammasomes, such as the NLR family, pyrin domain containing 3 (NLRP3) inflammasome, which contains a nucleotide binding domain leucine-rich repeat with a pyrin-domain containing 3 sensor, an apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) adaptor and a caspase-1 enzyme (7,8). For the secretion of IL-1β, pro-IL-1β must be cleaved by activated caspase-1. Caspase-1 is activated...
by an inflammasome assembly with NLRP3, ASC and pro-
caspase-1. LPS must induce IL-1β for caspase-1 activation in
response to adenosine triphosphate (ATP), which is a well-char-
acterized danger-associated molecular pattern (DAMP) (9,10).
Extracellular ATP promotes NLRP3 inflammasome activa-
tion by stimulating purinergic receptor P2X ligand-gated
ion channel 7 (P2X7) (11,12). Pro-caspase-1 association
with NLRP3 binds the adaptor molecule ASC, leading to
pro-caspase-1 activation, which, in turn, triggers pro-IL-1β
processing to mature IL-1β, in LPS- and ATP-stimulated cells.

Isothiocyanates are found abundantly in cruciferous or
‘cabbage family’ vegetables, such as garden cress, broccoli,
cabbage, kale, cauliflower and radish, and have been used as
diet components with potent chemopreventive and/or anti-
cancer properties (13,14). Certain isothiocyanates, such as
sulforaphane (SFN), phenethyl isothiocyanate (PEITC), and
benzyl isothiocyanate (BITC), are derived from glucosinolates
in cruciferous vegetables (15). Among several isothiocyanates,
BITC (C6H5-NS) (Fig. 1A) is an effector molecule in many
 cruciferous vegetable defense systems with antioxidant,
antitumor and anti-inflammatory activity (16-18). It has been
indicated that BITC exhibits anti-inflammatory activities (18);
however, to the best of our knowledge, no studies to date have
examined the effects of BITC on neuroinflammation, and in
particular, through inflammasome mediation. In the present
study, we examined the inhibitory effects of BITC against
IL-1β-induced expression in LPS-stimulated BV2 microglial
cells, as well as its effects on intracellular signaling pathways,
specifically inflammasome components.

Materials and methods

Reagents. We purchased LPS, BITC, diphenyleneiodo-
nium (DPI) and N-acetyl-L-cysteine (NAC) from Sigma
Chemical Co. (St. Louis, MO, USA); YCG 063 was obtained
from Millipore (Billerica, MA, USA). An antibody against
nuclear factor-xB (NF-xB) (cat. no. 14-6731) was obtained
from eBioscience (San Diego, CA, USA). The antibody
against NLRP3 (cat. no. AG-20B-0014) was purchased
from Adipogen (San Diego, CA, USA). An antibody against
IL-1β (cat. no. AF-401-NA) was purchased from R&D Systems
(Minneapolis, MN, USA). An antibody against caspase-1 (cat. no. sc-514) was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). The CellTiter-Glo®
Luminescent assay was purchased from Promega (Madison,
WI, USA).

Cell culture. The murine BV2 cell line, obtained from
Professor Eun-Hye Joe (Ajou University School of Medicine,
Suwon, Korea), was maintained in Dulbeco's modified Eagle's
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin
at 37°C in a humidified incubator with 5% CO2. Confluent
cultures were passed using trypsinization. For the experiments,
the cells were washed twice with warm DMEM (without phenol
red) and cultured in serum-free medium for 16 h prior to
the treatments. In all the experiments, the cells were treated with
various concentrations (1, 5 and 10 µM) of BITC for various
periods of time prior to stimulation with LPS (1 µg/ml) for the
indicated periods of time.

<table>
<thead>
<tr>
<th>Genes</th>
<th>NCBI no.</th>
<th>Primer sequences (5'-3')</th>
<th>Size (bp)</th>
</tr>
</thead>
</table>
| IL-1β       | NM_008361 | F: CTCGTGCTGTCGGAGCCATAT  
             | R: TTGAAGACAAACCGCTTTCCA  | 254      |
| NLRP3       | NM_145827 | F: CTGTGTGGGACTGAAACGAC  
             | R: GCAGCCCTGCTGTTTTGAC    | 543      |
| GAPDH       | NM_001289726 | F: TTCACCACCATGGAGAAAGGC  
             | R: GGCGATGGACTGTTGTCATGA  | 237      |

Determination of cell viability. Cell viability was assessed
using the Cell Counting kit-8 (CCK-8; Dojindo Laboratories,
Kumamoto, Japan). Briefly, wells containing 2x104 cells/ml
were treated with BITC (0, 1, 5, 10, 20 and 30 µM). Following
incubation for 24 h, the cells were washed twice with phos-
phate-buffered saline (PBS). CCK-8 was then added to each
well followed by incubation at 37°C for 1 h followed by an
analysis at 450 nm using a microplate reader (Model EL800;
Bio-Tek Instruments, Winooski, VT, USA).

Reverse transcriptase-polymerase chain reaction (RT-PCR).
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). Total RNA (1.0 µg) which was obtained
from the cells was reverse transcribed using M-MLV reverse
transcriptase (Promega) to produce cDNA. The RT-generated
cDNA encoding the IL-1β, NLRP3 and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) genes was amplified using
PCR and selective primers (Table I). Following amplification,
portions of the PCR reactions were subjected to agarose gel
electrophoresis.

Measurement of ATP levels. The total ATP content was
measured using the CellTiter-Glo® Luminescence assay kit
following the manufacturer’s instructions. Briefly, the assay
buffer and substrate were equilibrated to room temperature.
The buffer was transferred and gently mixed with the substrate
to obtain a homogeneous solution. Twenty microliters of the
culture medium and 20 µl of the assay reagent were added to
each well (384-well plate), and the content was gently mixed
under light protection on an orbital shaker. After 10 min,
the luminescence was measured using a Microplate Reader
(SpectraMax L; Molecular Devices, Devon, UK) at 570 nm.

Enzyme-linked immunosorbent assay (ELISA). The level of
IL-1β expression was measured using an ELISA kit (R&D Systems).
The cells were treated with various concentrations of NAC, DPI
and YCG 063 for 1 h prior to LPS stimulation (1 µg/ml). Following
incubation for 24 h, the culture supernatants were collected, and the IL-1β quantity
was measured. The results of ELISA were quantified using
an ELISA plate reader (Model EL800; Bio-Tek Instruments)
at 450 nm, which was corrected for absorbance at 540 nm in
accordance with the manufacturer's instructions.
**Western blot analysis.** The cells were washed 3 times with PBS and lysed with lysis buffer (Mammalian Cell-PE LB; G-Biosciences, St. Louis, MO, USA). Equal quantities of protein were separated on 10% sodium dodecyl sulfate (SDS)-polyacrylamide minigels and transferred onto nitrocellulose membranes. Following incubation with the appropriate primary antibody (IL-1β, NLRP3, caspase-1 and NF-κB), the membranes were incubated for 1 h at room temperature with a secondary antibody [goat anti-rabbit IgG (cat. no. 31460; Pierce, Rockford, IL, USA) goat anti-mouse IgG (cat. no. sc-2031; Santa Cruz BiotecnoLOGY, Inc.)] conjugated to horseradish peroxidase. Following 3 washes in Tris-buffered saline Tween-20 (TBST), the immunoreactive bands were visualized using the ECL detection system.

**Electrophoretic mobility shift assay (EMSA).** Nuclear extract was prepared using the NE-PER nuclear extraction reagent (Pierce). An oligonucleotide containing the immunoglobulin κ-chain binding site (κB, 5′-GATCTCAGAGGGGACTTTCCGAGAGA-3′) was synthesized as a probe for the gel retardation assay. A non-radioactive method in which the 3′ end of the probe was labeled with biotin was used (Pierce). The binding reactions contained 5 μg of nuclear extract protein, buffer (10 mM Tris, pH 7.5, 50 mM KCl, 5 mM MgCl₂, 1 mM dithiothreitol, 0.05% Nonidet P-40, and 2.5% glycerol), 50 ng of poly(dI-dC) and 20 fM of the biotin-labeled DNA. The reactions were incubated for 20 min at room temperature in a final volume of 20 μl. The competition reactions were performed by the addition of a 100-fold excess of unlabeled κB to the reaction mixture. The mixture was then separated using electrophoresis on a 5% polyacrylamide gel in 0.5X Tris-borate buffer and transferred to nylon membranes. The biotin-labeled DNA was detected using a LightShift chemiluminescent EMSA kit (Pierce).

**Statistical analysis.** Data values represent the means ± standard deviation (SD). To analyze the data produced from the experiments with 2 independent variables, one-way analysis of variance (ANOVA) was performed using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). Values of p<0.05, p<0.01 and p<0.001 were considered to indicate statistically significant differences.

**Results**

**Effects of BITC on BV2 microglial cell viability.** Initially, we examined the viability of the BV2 microglial cells treated with BITC (1, 5, 10, 20 and 30 μM) by CCK-8 assay. Treatment of the BV2 microglial cells with up to 10 μM BITC did not produce any cytotoxic effects, whereas cell viability was significantly decreased by 80 and 82% following treatment with 20 and 30 μM BITC, respectively (Fig. 1B). Based on these results, BITC at concentrations of 1, 5 and 10 μM was used in the subsequent experiments.

**Effects of BITC on IL-1β expression in LPS-stimulated BV2 microglial cells.** The IL-1β expression levels increased considerably following the stimulation of BV2 microglial cells with LPS (Fig. 2). The inhibitory effects of BITC on IL-1β mRNA and protein expression were determined using RT-PCR and ELISA, respectively. The IL-1β mRNA levels were markedly upregulated after 3 h of LPS (1 μg/ml) stimulation, and BITC significantly decreased the IL-1β mRNA expression levels in the LPS-stimulated BV2 microglial cells in a concentration-dependent manner (Fig. 2A). To evaluate the effects of BITC on IL-1β protein expression in the LPS-stimulated BV2 microglial cells, the cells were treated with BITC (1, 5 and 10 μM) for 1 h prior to LPS stimulation for 48 h. Treatment with BITC suppressed the LPS-induced increase in IL-1β protein expression in a concentration-dependent manner (Fig. 2B). The results of ELISA revealed that the reduction in IL-1β protein levels correlated with a reduction in the corresponding mRNA levels.

**Effects of BITC on NLRP3 and caspase-1 activation in LPS-stimulated BV2 microglial cells.** To determine whether BITC affects NLRP3 and caspase-1 activation, the BV2 microglial cells were stimulated with LPS in the presence or absence of BITC. LPS significantly increased NLRP3 mRNA expression (Fig. 3A). However, treatment with BITC attenuated the increase in NLRP3 mRNA expression. To evaluate the effects of BITC on NALP3 and caspase-1 protein expression in the LPS-stimulated BV2 microglial cells, we pre-treated the cells with BITC (1, 5 and 10 μM) prior to stimulation with LPS. Treatment with BITC suppressed the LPS-induced production of NLRP3 and caspase-1 (the subunit p10) activation in a concentration-dependent manner (Fig. 3B).

**Effects of BITC on ATP levels in LPS-stimulated BV2 microglial cells.** To quantify the total extracellular ATP levels, the BV2 microglial cells were stimulated with LPS in the presence or absence of BITC. LPS significantly increased the ATP levels (Fig. 4). To examine the effects of BITC on the ATP levels in LPS-stimulated BV2 microglial cells, we pre-treated the cells with BITC (1, 5 and 10 μM) prior to stimulation with...
LPS. Treatment with BITC prevented the LPS-induced increase in ATP levels.

**Involvement of mitochondrial ROS in NLRP3 and caspase-1 activation.** We examined whether the LPS-induced IL-1β production is associated with ROS generation (Fig. 5). First, the BV2 microglial cells were stimulated with LPS for 24 h in the presence or absence of ROS inhibitors, such as the ROS scavenger, NAC (2 or 5 mM), the NADPH oxidase inhibitor, DPI (0.1 or 0.2 µM), and the mitochondrial ROS inhibitor, YCG 063 (10 or 20 µM) (Fig. 5A). YCG 063 significantly inhibited the LPS-induced production of IL-1β. However, IL-1β expression was not altered in the cells pre-treated with NAC and DPI. To further determine the involvement of mitochondrial ROS in the inflammasome pathway, we analyzed inflammasome activation in the BV2 microglial cells. The immunoblot data showed that treatment with YCG 063 suppressed inflammasome activation, including NLRP3 and the active form of caspase-1 (Fig. 5B).

**Effects of BITC on NF-κB activation in LPS-stimulated BV2 microglial cells.** The production of IL-1β is regulated by the transcription factor, NF-κB. Furthermore, NF-κB plays a critical role in priming the NLRP3 inflammasome (19). Therefore, to elucidate the mechanisms through which BITC affects IL-1β expression, we examined the effects of BITC on NF-κB activation. We examined the effects of BITC on LPS-induced
NF-κB p65 nuclear translocation as NF-κB translocation to the nucleus is required for NF-κB-dependent transcription following LPS stimulation. The nuclear localization of NF-κB p65 was examined by western blot analysis. The results revealed that stimulation of the BV2 microglial cells LPS strongly induced NF-κB p65 nuclear localization. The LPS-induced NF-κB p65 translocation was abolished by pre-treatment of the cells with BITC (Fig. 6A). We then examined the effects of BITC on the nuclear factor-κB (NF-κB) translocation and binding to lipopolysaccharide (LPS)-stimulated BV2 microglial cell nuclei. The cells were treated with BITC (1, 5 and 10 µM) for 1 h and then stimulated with LPS for 2 h. (A) Nuclear extracts were prepared as described in the Materials and methods and NF-κB translocation was evaluated by western blot analysis. (B) Nuclear protein extracts were prepared and analyzed for NF-κB DNA binding activity using an electrophoretic mobility shift assay (EMSA). Cold-κB, unlabeled NF-κB probe.

Figure 6. Effect of benzyl isothiocyanate (BITC) on the nuclear factor-κB (NF-κB) translocation and binding to lipopolysaccharide (LPS)-stimulated BV2 microglial cell nuclei. The cells were treated with BITC (1, 5 and 10 µM) for 1 h and then stimulated with LPS for 2 h. (A) Nuclear extracts were prepared as described in the Materials and methods and NF-κB translocation was evaluated by western blot analysis. (B) Nuclear protein extracts were prepared and analyzed for NF-κB DNA binding activity using an electrophoretic mobility shift assay (EMSA). Cold-κB, unlabeled NF-κB probe.

Discussion

Neuroinflammation may be a common characteristic of various neurological and neurodegenerative disorders through release of proinflammatory cytokines and chemokines (20). A recent study demonstrated that inflammasome-mediated inflammation is involved in infectious diseases affecting the central nervous system (CNS) (21). In this respect, the regulation of inflammasome-mediated inflammatory pathways involved in infectious diseases affecting the CNS has gained attention. In this study, we investigated the inhibitory effects of BITC on IL-1β production in E. coli LPS-stimulated BV2 microglia. Additionally, we explored the several mechanisms involved in the inhibitory effects of BITC, specifically inflammasome-associated pathways.

Microglia are the resident macrophage cells and are widely distributed in the brain. In response to brain neuroinflammatory stimuli, activated microglia can overproduce pro-inflammatory and/or neurotoxic factors, including pro-inflammatory cytokines [IL-1, IL-6 and tumor necrosis factor-α (TNF-α)], nitric oxide (NO), prostaglandin E2 (PGE2) and ROS (22). These factors are involved in pathological conditions of various neurodegenerative diseases, such as AD, PD, MS, trauma and cerebral ischemia (23,24). Thus, reducing pro-inflammatory mediators in microglia may attenuate the severity of neurodegenerative disorders (25,26). Activated microglia are major cellular sources of the pro-inflammatory and/or cytotoxic factors that lead to neuronal damage in the CNS. Among the pro-inflammatory cytokines involved in neuroinflammation, IL-1β results from the inflammasome activation pathway. In this study, we demonstrate the inhibitory effects of BITC on low
levels of IL-1β production in ultrapure *E. coli* LPS-stimulated BV2 microglia without the addition of extracellular ATP.

LPS induces neuroinflammation by activating inflammatory cells, including astrocytes and microglial cells (27,28). In a previous study, systemically injecting LPS led to neuroinflammatory responses in the brain, leading to amyloid-β accumulation (Aβ), which is toxic to neurons (29). IL-1β is produced in LPS-stimulated BV2 microglia. The present study demonstrated that BITC inhibited IL-1β production in LPS-stimulated BV2 microglia (Fig. 2). The inflammasome is required for IL-1β maturation in LPS-stimulated BV2 microglia. In this regard, we investigated whether BITC inhibits IL-1β expression by suppressing inflammasome activation. The cells were stimulated with LPS followed by the assembly and activation of the inflammasome, which facilitated caspase-1 activation. Without extracellular ATP, the expression of NLRP3 and active caspase-1 markedly increased in response to LPS stimulation; however, treatment with BITC ameliorated this increase in a dose-dependent manner (Fig. 3). Therefore, the regulation of IL-1β production by BITC may be an effective means of inhibiting neuroinflammation through the attenuation of inflammasome activation.

Cell priming with LPS is necessary for ATP binding to surface-expressed P2X7 purinergic receptors (P2X7Rs), which are ATP-gated non-selective cation channels, to induce inflammasome activation, which results in IL-1β secretion (30). A recent study showed that P2X7Rs contribute to various CNS pathologies (31). ATP, a damaged associated molecular pattern, is released by any type of cell injury. ATP binding to P2X7R facilitates K+ efflux, which then activates the NLRP3 inflammasome (32). To determine whether BITC inhibits IL-1β production by altering ATP secretion, we measured the levels of secreted ATP in LPS-stimulated BV2 microglia. BITC decreased ATP secretion in a concentration-dependent manner (Fig. 4).

Although certain scholars debate this point, the field generally accepts the *in vitro* macrophage studies indicating that the activation and release of IL-1β via an NLRP3-inflammasome-dependent response requires two distinct signals: i) first, a priming signal can be triggered by pathogen-associated molecular pattern (PAMP) molecules, such as LPS, that target toll-like receptors and NF-κB, which leads to pro-IL-1β synthesis; ii) second, a signal can be derived from P2X7R activation, which leads to caspase-1 activation and the release of IL-1β (33,34). Therefore, LPS, the first signal, combined with ATP, the second signal, are commonly used to induce IL-1β production in microphages *in vitro*. However, LPS stimulation alone upregulated IL-1β production in our *in vitro* study (Fig. 2). In addition, we found that stimulation with LPS alone induced NLRP3 and caspase-1 activation (Fig. 3). Therefore, we examined whether LPS stimulation alone can induce ATP secretion. Of note, in our *in vitro* study, LPS stimulation alone significantly upregulated ATP secretion (Fig. 4). ATP acted in an autocrine mode when LPS stimulation alone was used for stimulation. Furthermore, while P2X7R did not induce expression with LPS stimulation, at almost basal levels, the BV2 cells constitutively expressed P2X7R (data not shown). However, BITC decreased ATP secretion in a concentration-dependent manner in the LPS-stimulated BV2 microglia (Fig. 4).

NLRP3 inflammasome activation has been widely implicated in ROS and NF-κB signaling (19,35). Therefore, NF-κB signaling and ROS levels were examined in this study. It has been proposed that ROS are an actual trigger for NLRP3 inflammasome assembly (36). Furthermore, potassium efflux triggers ROS production in human granulocytes (37). To investigate whether ROS production was responsible for the enhanced IL-1β production, we stimulated the cells with LPS in the presence of a mitochondrial ROS inhibitor or total ROS scavenger. In the present study, YCG 063, a mitochondrial ROS inhibitor, inhibited IL-1β production. However, NAC or DPI did not attenuate ROS production. In previous studies, mitochondrial-derived ROS were shown to be associated with NLRP3 activation (38-40). These data suggest that BITC attenuates NLRP3 activation via mitochondria-generated ROS inhibition. Furthermore, a previous study reported that NF-κB is involved in IL-1β, NLRP3 and caspase-1 expression (41). In previous studies, LPS-induced neuroinflammation was associated with upregulated NF-κB expression (42,43). Consistent with these studies, we investigated whether the treatment of LPS-stimulated BV2 microglia with BITC inhibits NF-κB activation. We found that BITC inhibited NF-κB activation. Collectively, based on these previous observations and our results, BITC likely attenuates IL-1β production and NLRP3 inflammasome activation by inhibiting mitochondrial ROS generation and NF-κB activation. Our results are consistent with those of previous publications, showing that LPS or NF-κB prime NLRP3 complex formation and ROS activate the NLRP3 complex (19,30,44).

In conclusion, our data demonstrate that BITC decreases IL-1β production in activated BV2 microglia. Our data also show that the decreased IL-1β production and the inhibition of NLRP3 inflammasome activation is associated with the attenuation of mitochondrial ROS generation and NF-κB activation by treatment with BITC. Thus, treatment with BITC may be an effective novel therapeutic strategy with which to combat inflammation-associated pathological damage which occurs due to LPS by targeting inflammasome-mediated signaling pathways. Further studies are warranted however, to determine whether BITC suppresses LPS-induced inflammasome-related neuroinflammation *in vivo*.

**Acknowledgements**

This study was supported by the Basic Science Research program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (no. 2013R1A1A4A0101649).

**References**


